Mental health is not just depression, schizophrenia, a mood disorder, anxiety; it has all of the things. We are trying to ...

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable depression. The HHS and FDA voice support for psychedelics.

Objective Ketamine and esketamine have both shown significant antidepressant effects in treatment-resistant depression (TRD) and conflicting evidence suggests that dissociation induced by these drugs ...

Our study focused on examining the use of esketamine in depression treatment over the past decade, using network diagrams to explore interactions among nations, educational institutions, journals, ...

Article citations More>> Pan, Y.Y., Qiao, N.N., Xu, G.P. and Qi, Q.L. (2023) Comparison of the Half Effective Dose of Sufentanil for Respiratory Depression When Combined with Different Doses of ...

A single dose of psilocybin, paired with therapy, brought long-lasting relief from depression and anxiety to cancer patients—effects that persisted even after two years.

The rise in non-prescribed ketamine use across the UK in recent years is a cause for concern, say doctors in The BMJ.

Objectives Subanaesthetic doses of esketamine may attenuate the opioid-induced cough reflex and prevent intraoperative haemodynamic fluctuations. This study aims to evaluate the effect of ...